Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Rossari BiotechNSE:ROSSARI +1.13%85 EV-to-EBIT is 13.05 as of Aug. 15, 2026, which is 47% below its 10-year median of 24.64. GuruFocus rates NSE:ROSSARI with a GF Score™ of 85/100 and a GF Value™ of ₹921.61 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 1,250 Chemicals companies, Rossari Biotech ranks better than 63.68% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Rossari Biotech's Enterprise Value for the quarter that ended in Jun. 2026 was ₹29,101 Mil.
Rossari Biotech's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹2,379 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rossari Biotech EV-to-EBIT Related Terms
Rossari Biotech EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Rossari Biotech's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:ROSSARI vs LIN, SHW, ECL: EV-to-EBIT Comparison
For the Specialty Chemicals subindustry, Rossari Biotech's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rossari Biotech EV-to-EBIT vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, Rossari Biotech's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Rossari Biotech's EV-to-EBIT falls into.
Rossari Biotech's current Enterprise Value is ₹31,035 Mil.
Rossari Biotech's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹2,379 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rossari Biotech (NSE:ROSSARI) has a EV-to-EBIT of 13.05 as of Aug. 15, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Rossari Biotech and its competitors. This is 47% below median its historical median of 24.64. Over the past decade, Rossari Biotech's EV-to-EBIT has ranged from 10.49 to 66.30. According to the industry distribution chart, Rossari Biotech ranks #454 out of 1250 companies in the Chemicals industry, placing it in the top 36.3%.
Is Rossari Biotech's EV-to-EBIT too high?
Rossari Biotech's current EV-to-EBIT of 13.05 is 47% below median its 10-year median of 24.64. Over the past 10 years, this metric has ranged from a low of 10.49 to a high of 66.30. The Chemicals industry median EV-to-EBIT is 17.81. Rossari Biotech's value of 13.05 is 26.7% below this industry median. Based on the distribution chart, Rossari Biotech ranks #454 out of 1250 companies in the Chemicals industry, which is above the industry midpoint. Overall, Rossari Biotech has a GF Score™ of 85/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Rossari Biotech's EV-to-EBIT compare to LIN and SHW?
According to the Chemicals industry distribution chart, Rossari Biotech ranks #454 out of 1250 companies for EV-to-EBIT. This puts Rossari Biotech in the upper half of its industry. The industry median EV-to-EBIT is 17.81. Rossari Biotech's value of 13.05 is 26.7% below this benchmark. Historically, Rossari Biotech's own EV-to-EBIT has ranged from 10.49 to 66.30 over the past decade. While the company's 10-year median is 24.64 vs. the industry median of 17.81, Rossari Biotech has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Chemicals company?
The median EV-to-EBIT among Chemicals companies is 17.81, based on 1,250 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Rossari Biotech's current EV-to-EBIT of 13.05 is 26.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Rossari Biotech and its competitors. For the Chemicals industry, the median EV-to-EBIT is 17.81 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rossari Biotech's current EV-to-EBIT is 13.05, which is 47% below median its own 10-year median of 24.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rossari Biotech stock overvalued right now?
Based on GuruFocus' analysis, Rossari Biotech (NSE:ROSSARI) is currently considered Possible Value Trap. The stock's GF Value™ is ₹921.61, compared to a current price of ₹503.00 — trading 45.4% below its estimated fair value. The current EV-to-EBIT is 13.05, which is 47% below median its 10-year median of 24.64 and 26.7% below the Chemicals industry median of 17.81. Rossari Biotech's overall GF Score™ is 85/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Rossari Biotech (NSE:ROSSARI), the current EV-to-EBIT is 13.05 as of Aug. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Rossari Biotech (NSE:ROSSARI) Overvalued in 2026?
Based on GuruFocus' analysis, Rossari Biotech stock appears to be undervalued.
The current stock price of ₹503.00 is trading 45.4% below its estimated GF Value™ of ₹921.61.
GuruFocus considers Rossari Biotech to be Possible Value Trap.
Key valuation signals for NSE:ROSSARI:
EV-to-EBIT: 13.05 (47% below median its 10-year median of 24.64)
GF Value™: ₹921.61 vs. price of ₹503.00 (45.4% below fair value)
Industry Position: 26.7% below the Chemicals median (#454 of 1250)
No single metric tells the full story. See the NSE:ROSSARI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Rossari Biotech Ltd is a specialty chemical manufacturing company. It provides customized solutions to specific industrial and production requirements of its customers in the FMCG, apparel, poultry, and animal feed industries through its product portfolio comprising home, personal care, and performance chemicals; textile specialty chemicals; and animal health and nutrition products. Its business is organized into three categories: home, personal care, and performance chemicals; textile specialty chemicals; and animal health and nutrition products. Its products include soaps and detergents, paints, inks and coatings, ceramics and tiles, water treatment chemicals, pulp and paper, and cleaning chemical formulations, among others. The company generates the majority revenue from India.
85GF Score
Get the complete analysis for NSE:ROSSARI
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ROSSARI has been successfully added to your 
